Elecsys® Troponin T-high sensitive

Enabling fast diagnosis of acute myocardial infarction

Roche Troponin T-high sensitive (cTnT-hs)
Make a difference when every minute counts

In the case of suspected AMI, prompt treatment is essential. Every 30 minutes of delay between symptoms and treatment increases the 1-year mortality rate by 7.5%.7

Troponin is the preferred biomarker in defining AMI according to the European Society of Cardiology (ESC) guidelines.8 In addition, it is the gold standard to distinguish between AMI and non-AMI patients.8,9

Elecsys® Troponin T-high sensitive (TnT-hs) can reduce the time needed to rule-in or rule-out NSTEMI to as little as just 1 hour.4-6


Supporting early and confident diagnosis with Elecsys® Troponin T-high sensitve1-6

As supported by the use of the 0/1 hour rule-in and rule-out algorithm recommended by international guidelines8

Safely reduce time to diagnosis

  • Triage over 75% of patients within 1 hour as validated by three multicenter studies with over 3,000 patients1-6
  • Safely rule-out AMI and confidently discharge patients based on a high negative predictive value (99.1% - 100%) and low 30 day mortality rate (0.0% - 0.2%)1-3

Lower the need for cardiac stress testing 

  • Significantly reduce the need for cardiac stress testing by exercise electrocardiogram (ECG)5, 10

Shorten stays in the emergency department (ED)

  • Facilitate early discharge or transfer from the ED by reducing time spent in ED by 2.1 hours (33%) vs standard practice4-6, 10, 11
Roche Troponin T-high sensitive (TnT-hs)

Assay specifications

  • Assay time

    9 minute STAT assay

  • 99th percentile upper reference limit

    14 ng/L (pg/mL)

  • 10% CV precision

    13 ng/L (pg/mL)

  • Sample material

    Heparin, EDTA plasma and serum


NSTEMI: non–ST-segment elevation myocardial infarction



  1. Reichlin T et al. (2012). Arch Int Med 172, 1211-8
  2. Reichlin T et al. (2015). CMAJ 187(8), e243-52
  3. Mueller C et al. (2016). Ann Emerg Med 68, 76-87
  4. Twerenbold R et al. (2019). JACC 74, 483 – 94
  5. Chew DP et al. (2019). Circulation 140, 1543-1556
  6. Stoyanov KM et al. (2020). Eur Heart J Acute Cardiovasc Care 9,39-51
  7. De Luca et al. (2004). Circulation 109, 1223-1225
  8. Collet JP et al. Eur Heart J 2021;42(14):1289-1367
  9. Thygesen K et al. (2019). Eur Heart J. 40, 237–269
  10. Twerenbold R et al. (2016). Eur Heart J. 37, 3324-32
  11. Ambavane A et al. (2017). PlosOne 12; e0187662